产品说明书

Lornoxicam

Print
Chemical Structure| 70374-39-9 同义名 : Chlortenoxicam;Ro 13-9297;TS 110;Xefocam;Lornoxicamum;Xefo
CAS号 : 70374-39-9
货号 : A152949
分子式 : C13H10ClN3O4S2
纯度 : 98%
分子量 : 371.819
MDL号 : MFCD00866163
存储条件：

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 3 mg/mL(8.07 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • COX-2

    COX-2, IC50:8 nM

  • COX-1

    COX-1, IC50:5 nM
描述 Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced cyclo-oxygenase (COX-1/COX-2) inhibition and excellent tolerability. Lornoxicam and rofecoxib are effective in the treatment of patients with activated osteoarthritis; the analgesic and anti-inflammatory effects of lornoxicam are significantly superior to those of rofecoxib without inferiority in tolerability[3]. The developed proniosomal gel (F19) improved the clinical efficacy of lornoxicam as compared to oral therapy. Graphical Abstract Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats[4]. Lornoxicam was also as effective as other NSAIDs in relieving symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01638962 Osteoarthritis, Knee Not Applicable Completed - Denmark ... 展开 >> University of Southern Denmark Odense, Region Syddanmark, Denmark, 5230 收起 <<
NCT02698995 Postoperative Pain Phase 3 Unknown July 2017 Romania ... 展开 >> Foisor Orthopedic Clinical Hospital Recruiting Bucharest, Romania, 021383 Contact: Ana Maria Munteanu, MD PhD    0040722514156    ammunteanu@gmail.com    Contact: Denisa Anastase, MD PhD    0040721255339    danastase1@gmail.com    Sub-Investigator: Simona Florescu Cionac, MD PhD          Sub-Investigator: Ioan Cristian Stoica, MD Prof 收起 <<
NCT01480752 Post Operative Endodontic Pain Phase 2 Completed - Iran, Islamic Republic of ... 展开 >> Dental School of Azad University Tehran, Iran, Islamic Republic of, 1946853314 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.45mL

2.69mL

1.34mL

26.89mL

5.38mL

2.69mL
参考文献

[1]Futaki N, Harada M, et al. The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. J Pharm Pharmacol. 2009 May;61(5):607-14.

[2]Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57.

[3]Rose P, Steinhauser C. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig. 2004;24(4):227-36

[4]Shah H, Nair AB, Shah J, Bharadia P, Al-Dhubiab BE. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats. Daru. 2019 Jun;27(1):59-70

[5]Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57